QY 301
Alternative Names: QY-301Latest Information Update: 29 Jun 2022
At a glance
- Originator E-nitiate Biopharmaceuticals
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Crohn's disease; Ulcerative colitis
Most Recent Events
- 29 Jun 2022 QY 301 is available for licensing as of 29 Jun 2022. http://www.enitiatebio.com/en.php/cooperation/
- 29 Jun 2022 E-nitiate Biopharmaceuticals plans to submit IND application for QY 301 in China and USA in Q4 of 2022 (E-nitiate Biopharmaceuticals pipeline, June 2022)
- 10 Dec 2021 E-nitiate Biopharmaceuticals has global patents for QY 301 before December 2021